1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
Year: 2020
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: S.S. Ramalingam, E. Thara, S. Rao, M.M. Awad, A. Dowlati, B. Haque, A.L. Veatch, T. Stinchcombe, G.K. Dy, D.R. Spigel, N. Iyer Singh, L. Evilevitch, Z. Wang, Y. Tang, I. Teslenko, M. Roychoudhury
Institutions: Emory University, Winship Cancer Institute, Oncology Institute of Hope and Innovation, Dana-Farber Cancer Institute, University Hospitals Seidman Cancer Center, Case Western Reserve University, Kadlec Clinic, Northwest Medical Specialties, Duke University, Duke Cancer Institute, Roswell Park Comprehensive Cancer Center, Sarah Cannon, Tennessee Oncology, GlaxoSmithKline (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: GlaxoSmithKline Australia
OpenAlex ID: W3088182148